cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-4-82-85cardiovascular-219Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMБЛОКАТОРЫ РЕЦЕПТОРОВ АНГИОТЕНЗИНА II И НЕФРОПРОТЕКЦИЯ: ПОЗИЦИИ ОЛМЕСАРТАНАANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTANФоминВ. В.FominV. V.

д. м.н., профессор, декан лечебного факультета, профессор кафедры терапии и профболезней медико-профилактического факультета

dean-lech@yandex.ruГБОУ ВПО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России, МоскваI.M. Sechenov First Moscow State Medical University, Moscow2013200820131248285Copyright © Фомин В.В., 20132013Фомин В.В.Fomin V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/219

Обсуждаются результаты экспериментальных и контролируемых клинических исследований, демонстрирующих нефропротективный эффект олмесартана. 

The paper presents the results of experimental studies and clinical trials which demonstrate nephroprotective effects of olmesartan. 

артериальная гипертензиясахарный диабетнефропротекцияолмесартанarterial hypertensiondiabetes mellitusnephroprotectionolmesartanReferencesBrenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.Viberti G, Wheeldon NM, MicroAlbuminuria Reduction wit VALsartan Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6): 672–6.Viberti G, Wheeldon NM, MicroAlbuminuria Reduction wit VALsartan Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6): 672–6.Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–8.Makino H, Haneda M, Babazono T et al.; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30 (6): 1577–8.Makino H, Haneda M, Babazono T et al.; INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30 (6): 1577–8.Chilman-Blair K, Rabasseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs of Today 2003; 39 (19): 745–61.Chilman-Blair K, Rabasseda X. Olmesartan, an AT1-selective antihypertensive agent. Drugs of Today 2003; 39 (19): 745–61.Ideura H, Hiromura K, Hiramatsu N, et al. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. Am J Physiol Renal Physiol 2007; 293 (4): F1214–21.Ideura H, Hiromura K, Hiramatsu N, et al. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy. Am J Physiol Renal Physiol 2007; 293 (4): F1214–21.Mima A, Matsubara T, Arai H, et al. Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Lab Invest 2006; 86 (9): 927–39.Mima A, Matsubara T, Arai H, et al. Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy. Lab Invest 2006; 86 (9): 927–39.Ihara G, Kiyomoto H, Kobori H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens 2010; 28 (11): 2289–98.Ihara G, Kiyomoto H, Kobori H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens 2010; 28 (11): 2289–98.Sofue T, Kiyomoto H, Kobori H, et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 2012; 25 (5): 604–11.Sofue T, Kiyomoto H, Kobori H, et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 2012; 25 (5): 604–11.Haller H, Ito S, Izzo JL, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.Haller H, Ito S, Izzo JL, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.Lindholm L, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.Lindholm L, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertenstion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10.FDA Drug Safety Communication: Ongoing safety review of Benicar and cardiovascular events. http: www.fda.gov.FDA Drug Safety Communication: Ongoing safety review of Benicar and cardiovascular events. http: www.fda.gov.Ruggenenti P, Fassi A, Ilieva AP. et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.Ruggenenti P, Fassi A, Ilieva AP. et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641–7.Mann JF, Gerstein HC, Yi QL, et al. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 2003; 14: 641–7.Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1–10.Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1–10.ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11–20.Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009; 151: 11–20.Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53 (1): 49–57.Ritz E, Viberti GC, Ruilope LM, et al. Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Diabetologia 2010; 53 (1): 49–57.Januszewicz A, Ritz E, Viberti G, et al. Office and ambulatory pulse pressure association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study). J Hum Hypertens 2011; 25 (11): 679–85.Januszewicz A, Ritz E, Viberti G, et al. Office and ambulatory pulse pressure association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study). J Hum Hypertens 2011; 25 (11): 679–85.Menne J, Izzo JL Jr, Ito S, et al.; ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012; 30 (4): 811–8.Menne J, Izzo JL Jr, Ito S, et al.; ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012; 30 (4): 811–8.Malacco E, Omboni S, Mallion JM, Volpe M; ESPORT Study Group. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status: a retrospective analysis. High Blood Press Cardiovasc Prev 2012; 19 (4): 213–22.Malacco E, Omboni S, Mallion JM, Volpe M; ESPORT Study Group. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status: a retrospective analysis. High Blood Press Cardiovasc Prev 2012; 19 (4): 213–22.Nishida Y, Takahashi Y, Nakayama T, et al. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol 2011; 10: 74.Nishida Y, Takahashi Y, Nakayama T, et al. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study. Cardiovasc Diabetol 2011; 10: 74.Koc Y, Mazi E, Sakaci T, et al. Effect of olmesartan on serum cystatin C levels in the patients with essential hypertension. Eur Rev Med Pharmacol Sci 2011; 15 (12): 1389–94.Koc Y, Mazi E, Sakaci T, et al. Effect of olmesartan on serum cystatin C levels in the patients with essential hypertension. Eur Rev Med Pharmacol Sci 2011; 15 (12): 1389–94.

The authors declare that there are no conflicts of interest present.